Lexicon Pharmaceuticals (LXRX) Expected to Post Earnings on Thursday

Key Points

• Lexicon Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast a loss of $0.06 per share and revenue of $4.14 million.
• The company’s previous quarter fell short of expectations, with a $0.06-per-share loss versus the $0.05 estimate and revenue of $0.69 million versus the $3.99 million consensus. Analysts project full-year and next-year losses of $0.17 and $0.24 per share, respectively.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating and a $5.70 price target, while LXRX recently traded at $1.49 and remains well below its 52-week high of $2.68.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Lexicon Pharmaceuticals to announce earnings of ($0.06) per share and revenue of $4.14 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. The firm had revenue of $0.69 million for the quarter, compared to analyst estimates of $3.99 million. On average, analysts expect Lexicon Pharmaceuticals to post ($0.17) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

Lexicon Pharmaceuticals Trading Up 0.7%

Lexicon Pharmaceuticals stock opened at $1.49 on Thursday. The company has a 50 day moving average price of $1.92 and a 200 day moving average price of $1.88. Lexicon Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $2.68. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37. The firm has a market capitalization of $662.98 million, a price-to-earnings ratio of -9.93 and a beta of 1.07.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LXRX shares. Cantor Fitzgerald began coverage on shares of Lexicon Pharmaceuticals in a research note on Monday, September 28th. They set an "overweight" rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 21st. Zacks Research cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 3rd. Finally, Wall Street Zen downgraded Lexicon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $5.70.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon's commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.